XML 31 R14.htm IDEA: XBRL DOCUMENT
v3.22.4

Note 6 - Goodwill and Intangible Assets, Net | 9 Months Ended
--- | ---
Dec. 31, 2022
Notes to Financial Statements |
Goodwill and Intangible Assets Disclosure [Text Block] | Note 6. Goodwill and Intangible Assets, Net Intangible assets, the significant majority of which are finite-lived, consist of the following:
|  | December 31, 2022 |  |  | March 31, 2022 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |
Customer relationships |  | $ | 237,412 |  |  | $ | (80,627 | ) |  | $ | 156,785 |  |  | $ | 244,157 |  |  | $ | (67,469 | ) |  | $ | 176,688 |
Intellectual property |  |  | 65,871 |  |  |  | (17,732 | ) |  |  | 48,139 |  |  |  | 65,893 |  |  |  | (12,620 | ) |  |  | 53,273 |
Other intangibles |  |  | 24,745 |  |  |  | (6,222 | ) |  |  | 18,523 |  |  |  | 25,350 |  |  |  | (5,194 | ) |  |  | 20,156 |
Total |  | $ | 328,028 |  |  | $ | (104,581 | ) |  | $ | 223,447 |  |  | $ | 335,400 |  |  | $ | (85,283 | ) |  | $ | 250,117 |
Amortization expense for finite-lived intangible assets acquired in a business combination was as follows:
|  | Three Months Ended December 31, |  |  | Nine Months Ended December 31, |
|  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Amortization in cost of revenues |  | $ | 1,695 |  |  | $ | 1,227 |  |  | $ | 5,094 |  |  | $ | 1,877 |
Amortization in general and administrative |  |  | 5,452 |  |  |  | 4,695 |  |  |  | 16,479 |  |  |  | 11,618 |
Total |  | $ | 7,147 |  |  | $ | 5,922 |  |  | $ | 21,573 |  |  | $ | 13,495 |
For the following fiscal years ending March 31, amortization expense is estimated as follows:
Remainder of 2023 |  | 7,250 |
2024 |  | 28,490 |
2025 |  | 26,911 |
2026 |  | 26,149 |
2027 |  | 25,652 |
The change in the carrying amount of goodwill was as follows:
|  | Clinical Genomics |  |  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Total |
March 31, 2022 |  | $ | 135,914 |  |  | $ | 29,750 |  |  | $ | 88,265 |  |  | $ | 37,237 |  |  | $ | 291,166 |
Effect of foreign currency translation |  |  | (244 | ) |  |  | (297 | ) |  |  | (7,871 | ) |  |  | (32 | ) |  |  | (8,444 | )
Goodwill related to Belyntic acquisition |  |  | - |  |  |  | - |  |  |  | 2,973 |  |  |  | - |  |  |  | 2,973 |
Measurement period adjustment - Agena acquisition |  |  | 114 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 114 |
December 31, 2022 |  | $ | 135,784 |  |  | $ | 29,453 |  |  | $ | 83,367 |  |  | $ | 37,205 |  |  | $ | 285,809 |
Goodwill acquired in the Biopharmaceutical Development division resulted from the Belyntic acquisition and is tax deductible.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI https://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration